Cincinnati Enquirer: 'Don't panic.' Anti-diabetes medication recalled, may contain high levels of cancer-causing compound

UC diabetes experts offers advice for patients in wake of recall

Two pharmaceutical companies issued voluntary recalls Monday for metformin, an anti-diabetes drug, due to high levels of a cancer-causing compound, according to the U.S. Food and Drug Administration. Metformin is used to treat type 2 diabetes, according to Mayo Clinic, and is distributed under the following brand names: Fortamet, Glucophage, Glucophage XR, Glumetza and Riomet.

The Cincinnati Enquirer spoke with Dr. Shailendra Patel, a professor and director of the UC Division of Endocrinology, Diabetes and Metabolism and UC Health physician, about the recall. He offered a message for patients who use metformin: do not quite the drug cold turkey.

"Don't panic," Patel told the Enquirer. "Just have a nice discussion with your provider. And make sure that if the medication's the only thing that's controlling your disease, don't stop it. Just go in and ask and say, 'what are my alternatives?' "

Read the full story in the Cincinnati Enquirer.

Learn more about Dr. Shailendra Patel.

Featured photo of blood sugar management device and generic medication courtesy of Unsplash.

Related Stories

1

Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy

March 16, 2026

Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.